Novartis has reached an agreement to buy Regulus Therapeutics and its experimental therapy for autosomal dominant polycystic kidney disease (ADPKD) for $800 million upfront in a deal that could ...

AstraZeneca has turned to another digital health partner to support its aspirations in chronic kidney disease (CKD), joining forces with Aptar to develop algorithms that can be used to detect CKD ...